211 related articles for article (PubMed ID: 37534695)
1. Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada.
Costiniuk CT; Singer J; Lee T; Galipeau Y; McCluskie PS; Arnold C; Langlois MA; Needham J; Jenabian MA; Burchell AN; Samji H; Chambers C; Walmsley S; Ostrowski M; Kovacs C; Tan DHS; Harris M; Hull M; Brumme ZL; Lapointe HR; Brockman MA; Margolese S; Mandarino E; Samarani S; Vulesevic B; Lebouché B; Angel JB; Routy JP; Cooper CL; Anis AH;
AIDS; 2023 Oct; 37(12):F25-F35. PubMed ID: 37534695
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy.
Cheung PK; Lapointe HR; Sang Y; Ennis S; Mwimanzi F; Speckmaier S; Barad E; Dong W; Liang R; Simons J; Lowe CF; Romney MG; Brumme CJ; Niikura M; Brockman MA; Brumme ZL;
AIDS; 2023 Apr; 37(5):F11-F18. PubMed ID: 36789806
[TBL] [Abstract][Full Text] [Related]
4. Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy.
Lapointe HR; Mwimanzi F; Cheung PK; Sang Y; Yaseen F; Speckmaier S; Barad E; Moran-Garcia N; Datwani S; Duncan MC; Kalikawe R; Ennis S; Young L; Ganase B; Omondi FH; Umviligihozo G; Dong W; Toy J; Sereda P; Burns L; Costiniuk CT; Cooper C; Anis AH; Leung V; Holmes D; DeMarco ML; Simons J; Hedgcock M; Prystajecky N; Lowe CF; Romney MG; Barrios R; Guillemi S; Brumme CJ; Montaner JSG; Hull M; Harris M; Niikura M; Brockman MA; Brumme ZL
AIDS; 2023 Apr; 37(5):709-721. PubMed ID: 36545783
[TBL] [Abstract][Full Text] [Related]
5. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P
Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccine immunogenicity in people with HIV.
Costiniuk CT; Singer J; Lee T; Langlois MA; Arnold C; Galipeau Y; Needham J; Kulic I; Jenabian MA; Burchell AN; Shamji H; Chambers C; Walmsley S; Ostrowski M; Kovacs C; Tan DHS; Harris M; Hull M; Brumme ZL; Lapointe HR; Brockman MA; Margolese S; Mandarino E; Samarani S; Vulesevic B; Lebouché B; Angel JB; Routy JP; Cooper CL; Anis AH;
AIDS; 2023 Jan; 37(1):F1-F10. PubMed ID: 36476452
[TBL] [Abstract][Full Text] [Related]
7. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
8. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
[TBL] [Abstract][Full Text] [Related]
9. Reduced maternal immunity and vertical transfer of immunity against SARS-CoV-2 variants of concern with COVID-19 exposure or initial vaccination in pregnancy.
Boelig RC; Chaudhury S; Gromowski GD; Mayer S; King J; Aghai ZH; Bergmann-Leitner E
Front Immunol; 2023; 14():1216410. PubMed ID: 37753075
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
11. Association Between Human Immunodeficiency Virus Viremia and Compromised Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant.
Hwa SH; Snyman J; Bernstein M; Ganga Y; Cele S; Muema D; Tan CW; Khan K; Karim F; Hanekom W; Bernstein L; Kaufmann SHE; Wang LF; Ndung'u T; Sigal A;
J Infect Dis; 2023 Jan; 227(2):211-220. PubMed ID: 35975942
[TBL] [Abstract][Full Text] [Related]
12. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
13. Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.
Benet S; Blanch-Lombarte O; Ainsua-Enrich E; Pedreño-Lopez N; Muñoz-Basagoiti J; Raïch-Regué D; Perez-Zsolt D; Peña R; Jiménez E; de la Concepción MLR; Ávila C; Cedeño S; Escribà T; Romero-Martín L; Alarcón-Soto Y; Rodriguez-Lozano GF; Miranda C; González S; Bailón L; Blanco J; Massanella M; Brander C; Clotet B; Paredes R; Esteve M; Izquierdo-Useros N; Carrillo J; Prado JG; Moltó J; Mothe B
J Infect Dis; 2022 Nov; 226(11):1913-1923. PubMed ID: 36200261
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV).
Khan K; Lustig G; Bernstein M; Archary D; Cele S; Karim F; Smith M; Ganga Y; Jule Z; Reedoy K; Miya Y; Mthabela N; Magula NP; Lessells R; de Oliveira T; Gosnell BI; Abdool Karim S; Garrett N; Hanekom W; Bekker LG; Gray G; Blackburn JM; Moosa MS; Sigal A;
Clin Infect Dis; 2022 Aug; 75(1):e857-e864. PubMed ID: 34893824
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
Front Immunol; 2022; 13():981693. PubMed ID: 36225911
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
[TBL] [Abstract][Full Text] [Related]
18. CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study.
Costiniuk CT; Singer J; Langlois MA; Kulic I; Needham J; Burchell A; Jenabian MA; Walmsley S; Ostrowski M; Kovacs C; Tan D; Harris M; Hull M; Brumme Z; Brockman M; Margolese S; Mandarino E; Angel JB; Routy JP; Anis AH; Cooper C
BMJ Open; 2021 Dec; 11(12):e054208. PubMed ID: 34916326
[TBL] [Abstract][Full Text] [Related]
19. High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2.
Pourcher V; Belin L; Soulie C; Rosenzwajg M; Marot S; Lacombe K; Valin N; Pialoux G; Calin R; Palacios C; Malet I; Zafilaza K; Tubiana R; Valantin MA; Klatzmann D; Calvez V; Simon-Tillaux N; Marcelin AG
AIDS; 2022 Sep; 36(11):1545-1552. PubMed ID: 35730380
[TBL] [Abstract][Full Text] [Related]
20. Lower T cell response against SARS-CoV-2 variants of concern after mRNA vaccine and risk of breakthrough infections in people with HIV.
Casado JL; Vizcarra P; Martín-Colmenarejo S; Del Pino J; Gomez-Maldonado S; Martín-Hondarza A; Vallejo A
AIDS; 2023 May; 37(6):877-882. PubMed ID: 36779501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
